fluphenazine decanoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1213 | 5002-47-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 20, 1972 | FDA | BRISTOL MYERS SQUIBB |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 100.89 | 52.77 | 27 | 452 | 17907 | 34938545 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuroleptic malignant syndrome | 140.24 | 41.55 | 36 | 767 | 27523 | 79716062 |
| Accommodation disorder | 42.45 | 41.55 | 7 | 796 | 591 | 79742994 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0016525 | Phenothiazines |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| CHEBI has role | CHEBI:37930 | phenothiazine antipsychotic drugs |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
| CHEBI has role | CHEBI:149553 | anticoronaviral drug |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| FDA EPC | N0000175746 | Phenothiazine |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Psychotic disorder | indication | 69322001 | |
| Alcoholism | contraindication | 7200002 | |
| Organophosphate poisoning | contraindication | 8260003 | |
| Weight gain finding | contraindication | 8943002 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Torsades de pointes | contraindication | 31722008 | |
| Parkinsonism | contraindication | 32798002 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Extrapyramidal disease | contraindication | 76349003 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Metabolic syndrome X | contraindication | 237602007 | DOID:14221 |
| Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| At risk for aspiration | contraindication | 371736008 | |
| Visual impairment | contraindication | 397540003 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Carcinoma of female breast | contraindication | 447782002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.85 | Basic |
| pKa2 | 3.85 | Basic |
| pKa3 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017722 | VUID |
| N0000179137 | NUI |
| D00793 | KEGG_DRUG |
| 4017722 | VANDF |
| 4019762 | VANDF |
| C0060580 | UMLSCUI |
| CHEBI:5124 | CHEBI |
| CHEBI:5123 | CHEBI |
| CHEMBL1200854 | ChEMBL_ID |
| C011825 | MESH_SUPPLEMENTAL_RECORD_UI |
| FMU62K1L3C | UNII |
| 3388 | PUBCHEM_CID |
| DB00623 | DRUGBANK_ID |
| 25190 | RXNORM |
| 3881 | MMSL |
| 4697 | MMSL |
| 4748 | MMSL |
| d00237 | MMSL |
| 001473 | NDDF |
| 001474 | NDDF |
| 372730004 | SNOMEDCT_US |
| 396063006 | SNOMEDCT_US |
| 41365009 | SNOMEDCT_US |
| D005476 | MESH_DESCRIPTOR_UI |
| C0016368 | UMLSCUI |
| 946 | INN_ID |
| 3372 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9529 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 14 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-838 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-129 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-129 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 17 sections |
| FLUPHENAZINE DECANOATE | Human Prescription Drug Label | 1 | 55150-267 | INJECTION, SOLUTION | 125 mg | INTRAMUSCULAR | ANDA | 11 sections |
| FLUPHENAZINE DECANOATE | Human Prescription Drug Label | 1 | 55150-267 | INJECTION, SOLUTION | 125 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-272 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64725-0272 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 11 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-359 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 15 sections |
| Fluphenazine Decanoate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-359 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 15 sections |
| fluphenazine decanoate | Human Prescription Drug Label | 1 | 68083-476 | INJECTION, SOLUTION | 25 mg | INTRAMUSCULAR | ANDA | 15 sections |